Charles Schwab Investment Management Inc Summit Therapeutics Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 876,390 shares of SMMT stock, worth $16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
876,390
Previous 1,291,671
32.15%
Holding current value
$16 Million
Previous $27.5 Million
33.9%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SMMT
# of Institutions
271Shares Held
92.9MCall Options Held
5.19MPut Options Held
3.39M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...